Riboscience, a clinical-stage biotechnology company developing first-in-class immunotherapies, today announced that Phase 1b data for RBS2418, its lead oral ENPP1 inhibitor, will be presented in a ...
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class ...
Summit Therapeutics Inc. announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 /VEGF ...
The ACME XP60 revives the Oberheim Xpander Synthesizer in a compact design, staying true to its original architecture. It’s ...
"Next-Generation M&A Encyclopedia - Designing 'Want to Sell and Want to Buy'"Today's Headlines AI Storm transfers two data ...
The catalytic and other sophisticated functions of biomolecules arise from the placement of many atoms in three-dimensional ...
Enables expansion of ongoing vitiligo clinical study to U.S. investigational sites; Topline data anticipated Q4 2027; TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc ...
How-To Geek on MSN
Affinity's AI layer splitter turns a flattened PNG into a workable composition, with one catch
Turning uneditable files into workable layers, but there's a catch ...
Tech Times on MSN
Plain-English AI produces validated drug-candidate proteins against rare disease target
AI protein design leapt forward: University of Washington researchers built Prompteina, the first model generating 3D protein ...
When hearing the name "Canva," many in Japan may still have the image of it being a "simple design tool for individual ...
Lithium-metal battery research gets a major advance: scientists at UNIST and KAIST showed two cheap commodity solvents triple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results